Genmab's stock is seeing significant social media buzz, with X driving most of the engagement. Discussions are focused on upcoming earnings and antibody-drug conjugate mechanisms, though a critical theme highlights a trial failure for their drug Epkinly.
Genmab is a biotechnology company focused on developing and manufacturing antibody therapeutics.
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Month: [-------] +23%
[--] Months: [---------] +68%
[--] Year: [---------] +20%
1-Year High: [-------] on 2025-09-29
1-Year Low: [---] on 2025-12-14
Engagements by network (24h): Reddit: [--] X: [-----] YouTube: [--]
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-08
1-Year Low: [--] on 2025-04-19
Mentions by network (24h): Reddit: [--] X: [--] YouTube: [--]
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $gmab in the last [--] hours which is down 38% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-11-08
1-Year Low: [--] on 2025-04-19
The most influential creators that mention $gmab in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @MarcJacksonLA | [--] | [-----] | [--] | [---] |
| @EarningsSeason_ | [--] | [---] | [--] | [---] |
| @LayanAhmed5637 | [--] | [--] | [--] | [--] |
| @NightOwlBiotech | [--] | [-----] | [--] | [--] |
| @EgidiusLambrech | [--] | [---] | [--] | [--] |
| @investingportfoliopathway | [--] | [---] | [--] | [--] |
| @JacobPlieth | [--] | [------] | [--] | [--] |
Sentiment 24-Hour Time-Series Raw Data
Current Value: 100%
Daily Average: 83%
[--] Month: 75% -1%
[--] Months: 75% -25%
[--] Year: 75% -4%
1-Year High: 100% on 2025-03-04
1-Year Low: 42% on 2025-11-29
Most Supportive Themes:
Most Critical Themes:
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$DKNG -Wells Fargo lowers DraftKings target to $30 from $49 Overweight -Bernstein lowers target to $28 from $32 Overweight - $EXP -JPMorgan downgrades Eagle Materials to Underweight from Neutral Lowers target to $215 from $230 - $GMAB -Morgan Stanley maintains Genmab $34 target = Weight - https://twitter.com/i/web/status/2023540997523992983 https://twitter.com/i/web/status/2023540997523992983"
X Link @MarcJacksonLA 2026-02-16T23:32Z [----] followers, [---] engagements
"30 stocks with 30% net profit margins (cash machines ✅): $NVDA $APP $AVGO $DUOL $TSM $GOOG $PLTR $IIPR $FUTU $EXEL $GMAB $CHKP $PANW $META $IREN $LLY $MSFT $TCOM $ANET $HOOD $MA $EXOD $DOCS $GSL $PSA $MU $VICI $NVO $V $KLAC Some of my favorites are on here"
X Link @LEAPTRADER_ 2026-02-13T22:05Z 27K followers, 13.5K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing